Why Does Pnemococcus Kill?

Author:

Bergeron Yves1,Bergeron Michel G1

Affiliation:

1. Centre de Recherche en lnfectiologie, Université Laval, Ste-Foy, Québec, Canada

Abstract

Acute lower respiratory tract infections remain the most common cause of death due to infection worldwide, andStreptococcus pneumoniaeis responsible for approximately 30% of all cases of community-acquired pneumonia. While many virulence factors have been associated with fatal pneumococcal pneumonia. there is growing evidence that some components of the immune response contribute significantly to the high mortality rate. This paper reviews the major bacterial virulence factors and pathogenesis steps that characterize fatal pneumococcal pneumonia, with a focus on the inflammation that was observed from the initial infection to death in an experimental murine pneumonia model. These steps involve the successive recruitment of polymorphonuclear neutrophils (PMNs). monocytes and lymphocytes; the pulmonary and/or systemic release of inflammatoty mediators that characterize the prebacteremic and bacteremic phases of infection; and the participation of parenchymal cells in the host response. Although the kinetics of cytokines differ considerably from blood to lung tissue to alveoli, and blood levels do not correlate to tissue levels, the kinetics of tumour necrosis factor (TNF) and interleukin-6 in blood, as well as TNF and nitric oxide in bronchoalveolar lavage (BAL) fluid are good indicators of the evolution of the disease. Nitric oxide release is biphasic and corresponds mostly to monocyte recruitment in BAL fluid and concomitant serious tissue injury. Pneumococci activate leukotriene B4(LTB4) release. but PMN recruitment is not primarily mediated by LTB4. Bacteremia, leukopenia, thrombocytopenia and lipid peroxidation closely precede death. Knowledge of the chronology of microbiological and inflammatory events that occur during pneumonia may help to design appropriate diagnostic tests that could be used to monitor the evolution of this deadly infection. There has been an explosive growth in the use of biological response modifiers that may be given to treat pneumonia. The proper use of these agents requires prior identification of biological markers in humans with pneumonia.

Publisher

Hindawi Limited

Subject

Microbiology (medical)

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3